Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.50 |
| ▸ | HPGDS | O60760 | 5/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61833 | 0.92 | HDAC4 (0.49) | GPR119HPGDSPRKAA2CHEK2HDAC4 | |
| SCHEMBL5020463 | 0.86 | HPGDS (0.55) | HPGDSPRKAA2 | |
| SCHEMBL12199848 | 0.83 | GPR119 (0.50) | GPR119LMNANPBWR1MCHR1CHEK2 | |
| SCHEMBL12199795 | 0.83 | GPR119 (0.50) | GPR119LMNANPBWR1MCHR1CHEK2 | |
| SCHEMBL4403520 | 0.81 | GPR119 (0.52) | GPR119LMNANPBWR1MCHR1MEN1 | |
| SCHEMBL16194601 | 0.81 | PRKAA2 (0.48) | HPGDSPRKAA2 | |
| SCHEMBL4405719 | 0.81 | GPR119 (0.52) | GPR119LMNANPBWR1MCHR1MEN1 | |
| SCHEMBL2696228 | 0.81 | HPGDS (0.46) | HPGDSPRKAA2 | |
| SCHEMBL4408236 | 0.80 | GPR119 (0.52) | GPR119LMNANPBWR1MCHR1MEN1 | |
| SCHEMBL61133 | 0.80 | HDAC4 (0.53) | HPGDSHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895578-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8557822-B2 | Carboxamide, sulfonamide and amine compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108606-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | GPR119 35/4885HPGDS 3138/4885PRKAA2 3/4885 |
| US-20140045882-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using The Same | AK2, PRKAA1, PRKAA2 | GPR119 35/4885HPGDS 3138/4885PRKAA2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.